VIVS VivoSim Labs, INC.

CIK 0001497253 22 ready 8-Ks latest April 3, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 22

Latest filing April 3, 2026, 7:59 PM ET

Top materiality 0.80

Event mix other_material ×13 · regulatory ×3 · m_and_a ×3

Sentiment 6 pos · 3 neg · 13 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for VIVS

Highest-materiality recent filing

Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting

February 25, 2025, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 3.01 item 8.01 item 9.01

Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.

Read filing →

April 3, 2026, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

VivoSim prices up to $4M public offering, closes initial $3M tranche

Initial closing raised $3M at $1.14/share; 286,557 shares + 2,345,022 pre-funded warrants sold.
August 14, 2025, 7:59 PM ET leadership materiality 0.60 positive item 5.02 item 7.01 item 9.01

VivoSim Labs appoints Tony Lialin as Chief Commercial Officer

Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
May 6, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

VivoSim Labs regains compliance with Nasdaq minimum equity and bid price rules

On April 30, 2025, Nasdaq confirmed VivoSim Labs demonstrated compliance with minimum $2.5M stockholders' equity and $1.00 bid price requirements.
April 24, 2025, 7:59 PM ET other material materiality 0.70 positive item 5.03 item 7.01 item 8.01 item 9.01

Organovo Holdings renames to VivoSim Labs, emerges from stealth to target FDA animal testing phase-out

Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.
March 27, 2025, 7:59 PM ET M&A materiality 0.60 positive item 7.01 item 9.01

Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026

FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
March 26, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01 item 5.02 item 8.01 item 9.01 ◈ executive_change

Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones

Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.
March 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 9.01

Organovo implements 1-for-12 reverse stock split to regain Nasdaq minimum bid price compliance

Reverse stock split at ratio 1-for-12, effective March 20, 2025, to combine every 12 shares into 1.
February 25, 2025, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 3.01 item 8.01 item 9.01

Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting

Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.
January 17, 2025, 6:59 PM ET regulatory materiality 0.80 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Organovo receives Nasdaq delisting notice for bid price non-compliance; intends to appeal with reverse split plan

Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.
December 31, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement

Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.
November 22, 2024, 6:59 PM ET other material materiality 0.60 negative item 5.02 item 5.07 item 9.01

Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase

Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.
July 24, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 item 9.01

Organovo received Nasdaq delisting notice for bid price below $1 per share

Nasdaq notice on July 18, 2024: closing bid price below $1 for 30 consecutive business days.
May 13, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements ×2

Organovo prices $5.25M public offering of common stock and warrants

Offering of 6.56M units at $0.80/unit; gross proceeds $5.25M before expenses.
April 23, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Organovo issues 1.35M shares for ~$1.8M under ATM facility

Issued 1,349,778 shares between Feb 1 and Apr 19, 2024; gross proceeds of $1.8 million.

Executive changes

Departed

Vaidehi Joshi

Director

VIVS · VivoSim Labs, INC.

Effective: 2025-03-21
Filed: March 26, 2025, 7:59 PM ET

On March 21, 2025, Vaidehi Joshi notified the Board of Directors (the "Board") of the Company that she resigned from the Board and all committees of the Board, effective as of March 21, 2025.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event other_material

6 positive 3 negative 13 neutral

source · VIVS on sec.gov